Tian Yueru, Li Tianming, Zhu Yuanjun, Wang Bei, Zou Xue, Li Min
Department of Laboratory Medicine, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
BMC Microbiol. 2014 Nov 25;14:292. doi: 10.1186/s12866-014-0292-5.
Linezolid is one of the most effective treatments against Gram-positive pathogens. However, linezolid-resistant/intermediate strains have recently emerged in worldwide. The purpose of this study was to analyse the prevalence and resistance mechanisms of linezolid-resistant/intermediate staphylococci and enterococci in Shanghai, China.
Thirty-two linezolid-resistant/intermediate strains, including 14 Staphylococcus capitis, three Staphylococcus aureus, 14 Enterococcus faecalis and one Enterococcus faecium clinical isolates, were collected in this study which displayed linezolid MICs of 8 to 512 μg/ml, 8-32 μg/ml, 4-8 μg/ml and 4 μg/ml, respectively. All linezolid-resistant S. capitis isolates had a novel C2131T mutation and a G2603T mutation in the 23S rRNA region, and some had a C316T (Arg106Cys) substitution in protein L4 and/or harboured cfr. Linezolid-resistant S. aureus isolates carried a C389G (Ala130Gly) substitution in protein L3, and/or harboured cfr. The cfr gene was flanked by two copies of the IS256-like element, with a downstream orf1 gene. Linezolid-resistant/intermediate enterococci lacked major resistance mechanisms. The semi-quantitative biofilm assay showed that 14 linezolid-resistant E. faecalis isolates produced a larger biofilm than linezolid-susceptible E. faecalis strains. Transmission electron microscopy showed the cell walls of linezolid-resistant/intermediate strains were thicker than linezolid-susceptible strains.
Our data indicated that major resistance mechanisms, such as mutations in 23S rRNA and ribosomal proteins L3 and L4, along with cfr acquisition, played an important role in linezolid resistance. Secondary resistance mechanisms, such as biofilm formation and cell wall thickness, should also be taken into account.
利奈唑胺是治疗革兰氏阳性病原体最有效的药物之一。然而,耐利奈唑胺/中介菌株最近在全球范围内出现。本研究的目的是分析中国上海耐利奈唑胺/中介葡萄球菌和肠球菌的流行情况及耐药机制。
本研究收集了32株耐利奈唑胺/中介菌株,包括14株头状葡萄球菌、3株金黄色葡萄球菌、14株粪肠球菌和1株屎肠球菌临床分离株,其利奈唑胺的最低抑菌浓度分别为8至512μg/ml、8 - 32μg/ml、4 - 8μg/ml和4μg/ml。所有耐利奈唑胺的头状葡萄球菌分离株在23S rRNA区域有一个新的C2131T突变和一个G2603T突变,有些在蛋白L4中有C316T(Arg106Cys)替代和/或携带cfr基因。耐利奈唑胺的金黄色葡萄球菌分离株在蛋白L3中有C389G(Ala130Gly)替代和/或携带cfr基因。cfr基因两侧有两个拷贝的IS256样元件,下游有一个orf1基因。耐利奈唑胺/中介肠球菌缺乏主要耐药机制。半定量生物膜试验表明,14株耐利奈唑胺的粪肠球菌分离株产生的生物膜比敏感粪肠球菌菌株更大。透射电子显微镜显示,耐利奈唑胺/中介菌株的细胞壁比敏感菌株更厚。
我们的数据表明,主要耐药机制,如23S rRNA和核糖体蛋白L3和L4的突变以及获得cfr基因,在耐利奈唑胺中起重要作用。还应考虑生物膜形成和细胞壁厚度等次要耐药机制。